Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ‐MY20) in Portuguese myeloma patients

Pereira, M. Graça; Ferreira, Gabriela; Faria, Sara; Bacalhau, Rosário; Monteiro, Sara; Fernandes, Bruna; Vilaça, Margarida

doi:10.1111/ecc.13128

Cited by 4 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four validation studies highlighted potential ceiling effects for the BI subscale. No issues with item reliability (Cronbach’s alpha) were identified for the multi-item scales [ 10 , 17 , 25 – 27 , 29 , 30 ]. Test-retest reliability was assessed in one article [ 25 ]; all four QLQ-MY20 subscales had high test-retest reliability (ICC ≥ = 0.85).…”

Section: Resultsmentioning

confidence: 99%

“…Test-retest reliability was assessed in one article [ 25 ]; all four QLQ-MY20 subscales had high test-retest reliability (ICC ≥ = 0.85). Two articles assessing factor analysis were inconsistent with one showing acceptable fit [ 25 ] and one suggesting item reduction in the SE subscale [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

“…Nine validation studies were identified in the review [10,17,[25][26][27][28][29][30][31]. Four validation studies highlighted potential ceiling effects for the BI subscale.…”

Section: Qlq-my20 Validation Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

Forde¹,

Cocks²,

Wells³

et al. 2023

Blood Cancer J.

View full text Add to dashboard Cite

The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in patients with myeloma and new combination agents are likely to impact HRQoL outcomes and its measurement.The aim of this review was to explore the use of the QLQ-MY20 and reported methodological issues.An electronic database search was conducted (1996-June 2020) to identify clinical studies/research that used the QLQ-MY20 or assessed its psychometric properties. Data were extracted from full-text publications/conference abstracts and checked by a second rater.The search returned 65 clinical and 9 psychometric validation studies. The QLQ-MY20 was used in interventional (n = 21, 32%) and observational (n = 44, 68%) studies and the publication of QLQ-MY20 data in clinical trials increased over time. Clinical studies commonly included relapsed patients with myeloma patients (n = 15, 68%) and assessed a range of combinations therapies.QLQ-MY20 subscales (disease symptoms [DS], side effects of treatment [SE], future perspectives [FP], body image [BI]) were defined as secondary (n = 12, 55%) or exploratory (n = 7, 32%) trial endpoints, particularly DS (n = 16, 72%) and SE (n = 16, 72%). Validation articles demonstrated that all domains performed well regarding internal consistency reliability (>0.7), test-reset reliability (intraclass correlation coefficient > =0.85), internal and external convergent and discriminant validity. Four articles reported a high percentage of ceiling effects in the BI subscale; all other subscales performed well regarding floor and ceiling effects.The EORTC QLQ-MY20 remains a widely used and psychometrically robust instrument. While no specific problems were identified from the published literature, qualitative interviews are ongoing to ensure new concepts and side effects are included that may arise from patients receiving novel treatments or from longer survival with multiple lines of treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

Forde¹,

Cocks²,

Wells³

et al. 2023

Blood Cancer J.

View full text Add to dashboard Cite

show abstract

“…Module 25,26 The original version of the Multiple Myeloma Module (QLQ-MY) consists of 20 items that assess the impact of MM and its treatment on patients. Questions focus on disease symptoms (MYDS; 6 items), side-effects of treatment (MYSE; 10 items), future perspective (MYFP; 3 items), and body image (MYBI; 1 item), using a 4-point Likert scale.…”

Section: The European Organization For Research and Treatment Of Cancmentioning

confidence: 99%

Validation of the Short‐Form Survivor Unmet Needs Survey in older patients with myeloma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Multiple myeloma (MM) affects mainly the older population and is the second most prevalent haematologic cancer. MM patients' unmet needs are diverse, arise at different stages, and are associated with greater psychological distress. This study examined the psychometric properties of the Short‐Form Survivor Unmet Needs Survey (SF‐SUNS) in Portuguese MM patients. Methods This cross‐sectional study included 213 MM patients. The internal consistency of the scale was analyzed with Cronbach's α. Principal component analysis and confirmatory factor analysis were used to assess construct validity. Convergent validity was examined by using correlations with quality of life, satisfaction with social support, and psychological morbidity. Multiple regression analyses were conducted to explore the contribution of sociodemographic and clinical variables to unmet needs. Results The Portuguese SF‐SUNS's factor structure follows the original's structure, although it includes fewer items. For each domain, Cronbach's α was ≤0.70, the minimum acceptable criterion. For construct validity, only unmet relationship and emotional needs had significant correlations (r ≥ 0.40)—specifically negative associations with quality of life and social support and positive associations with psychological morbidity. Regarding patient variables and SF‐SUNS results, only cancer stage contributed significantly to unmet information needs, with patients at stage I reporting more needs than patients at stage III. Conclusions The SF‐SUNS represents a valid and reliable tool to assess unmet needs among Portuguese MM patients. It may be useful in designing and monitoring interventions to improve well‐being in cancer survivors.

show abstract

“…Higher scores on the symptom scales reflect a greater number of symptoms, while on the functional scale/ item, higher scores reveal better future prospects and body image. The Portuguese QLQ-MY version [35], used in this study, comprises 17 of the 20 original items (MYSE contains less 3 items) distributed among the same four scales, with good internal consistency (MYDS: α = 86; MYSE: α = 0.68; MYFP: α = 91). Cronbach's alphas in the present study were 0.86 for MYDS, 0.68 for MYSE and 0.95 for MYFP.…”

Section: Instrumentsmentioning

confidence: 99%

The mediator role of unmet needs on quality of life in myeloma patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Purpose The diagnosis of multiple myeloma (MM) has a significant impact on patients. This study analyzed the mediating role of patients' unmet needs in the relationship between psychological morbidity/social support and quality of life (QoL). Methods This study included 213 patients with MM recruited from the outpatient medical oncology and clinical hematology services from five hospitals. Patients who meet the study criteria were referred by physicians and invited to participate in the study by the researcher. All participants answered the following questionnaires: Hospital Anxiety and Depression Scale, Satisfaction with Social Support Scale, Short-Form Survivor Unmet Needs Survey, and The European Organization for Research and Treatment of Cancer's Multiple Myeloma Module. Descriptive statistics, bivariate correlations, and structural equation modeling were performed to analyze the data. ResultsThe indirect effect of psychological morbidity on patients' future perspectives (MYFP) was partially mediated by information unmet needs (INF), while the indirect effect of psychological morbidity on treatment side effects (MYSE) was partially mediated by relationship and emotional unmet needs (REH). In turn, the indirect effect of psychological morbidity on disease symptoms (MYDS) was fully mediated by REH. Social support had an indirect effect on MYDS and MYSE fully mediated by REH. Conclusion Intervention programs tailored to promote MM patients' QoL should specifically address information and emotional needs, raising awareness and training health professionals, caregivers, and family members to attend MM patients' unmet needs.

show abstract

Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ‐MY20) in Portuguese myeloma patients

Cited by 4 publications

References 44 publications

Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

Validation of the Short‐Form Survivor Unmet Needs Survey in older patients with myeloma

The mediator role of unmet needs on quality of life in myeloma patients

Contact Info

Product

Resources

About